Search stocks

Find any stock by ticker or company name

Home

LXEO

Lexeo Therapeutics, Inc. (LXEO)

NGM – Real Time Price. Currency in USD

4.95

+0.17 (3.48%)

Market open: Aug 12, 2026, 11:37 AM EDT

4.87

+0.09 (1.88%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Instagram
Telegram
LinkedIn

Home
Watchlist
Markets
Calendar
Screener
News
About

LXEO - Lexeo Therapeutics, Inc. Latest News | Finranks

Home

LXEO

Lexeo Therapeutics, Inc. (LXEO)

NGM – Real Time Price. Currency in USD

4.95

+0.17 (3.48%)

Market open: Aug 12, 2026, 11:37 AM EDT

4.87

+0.09 (1.88%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

05.08.2026

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM

Videos

No Data

There is no data to display

Press releases

05.08.2026

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM

05.08.2026

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM

Videos

No Data

There is no data to display

Press releases

05.08.2026

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM

Search stocks

Lexeo Therapeutics, Inc. (LXEO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Videos

No Data

Press releases

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Videos

No Data

Press releases

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy